Skye Bioscience reports positive Phase 1b results for liver disease drug

Skye Bioscience (NASDAQ:SKYE) announced positive Phase 1b safety and tolerability results for its CB1-inhibiting antibody nimacimab in metabolic-associated steatotic liver disease (MASLD) patients, with no neuropsychiatric safety signals, supporting its advancement into a Phase 2a obesity trial, including combination with GLP-1 agonists, following promising preclinical weight loss data. While the company's stock has experienced significant momentum, trading near $57 with a 26.9% annual return, JMP Securities reiterated a Market Outperform rating but set a price target of $15.00, notably below current trading levels. Despite being unprofitable, Skye maintains strong financial health with cash reserves exceeding debt.

Analysis

Skye Bioscience (NASDAQ:SKYE) has reported a favorable safety and tolerability profile for its CB1-inhibiting antibody, nimacimab, from a Phase 1b study in MASLD patients. The key takeaway is the absence of neuropsychiatric safety signals, a crucial differentiator in a market wary of such side effects from previous anti-obesity drugs. These results, combined with promising preclinical data showing over 40% weight loss in mice when nimacimab is paired with a GLP-1 agonist, support the ongoing Phase 2a trial in obesity. Financially, the company maintains a strong balance sheet with cash exceeding debt and a high proprietary financial health score of 3.65, providing a solid foundation for its significant R&D expenditures, which resulted in a Q2 2025 net loss of $17.6 million. Despite strong stock momentum, with a 26.9% one-year return bringing the price near $57, a significant discrepancy exists in analyst coverage. JMP Securities reiterated a 'Market Outperform' rating but with a price target of $15.00, substantially below the current trading price, introducing a major point of valuation uncertainty for investors to reconcile against the positive clinical developments.

Key Decisions for Investors

• Investors should weigh the promising clinical profile of nimacimab, specifically its favorable safety data, as a potential de-risking event for its obesity pipeline, which could position it as a complementary or alternative therapy in the lucrative GLP-1 market.
• The significant disconnect between the current stock price near $57 and the JMP Securities price target of $15.00 warrants extreme caution; this valuation gap must be investigated as it may signal considerable downside risk despite the positive analyst rating and recent news.
• Given the company is pre-profitability and investing heavily in R&D, upcoming results from the Phase 2a CBeyond clinical trial represent a key binary catalyst that will either validate the current valuation or align it closer to more conservative targets.